Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.

Gouni-Berthold I, Berthold HK.

Am Heart J. 2002 Feb;143(2):356-65. Review.

PMID:
11835043
2.

Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.

Castaño G, Más R, Arruzazabala ML, Noa M, Illnait J, Fernández JC, Molina V, Menéndez A.

Int J Clin Pharmacol Res. 1999;19(4):105-16.

PMID:
10939028
3.

Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.

Castaño G, Mas R, Fernández L, Illnait J, Gámez R, Alvarez E.

Int J Clin Pharmacol Res. 2001;21(1):43-57.

PMID:
11708574
4.

Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.

Castaño G, Fernández L, Mas R, Illnait J, Gámez R, Mendoza S, Mesa M, Fernández J.

Drugs R D. 2005;6(4):207-19.

PMID:
16050054
5.

Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.

Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB.

Am Heart J. 2006 Nov;152(5):982.e1-5.

PMID:
17070175
6.

Policosanol: a new treatment for cardiovascular disease?

Janikula M.

Altern Med Rev. 2002 Jun;7(3):203-17. Review.

7.

Effect of sugar cane policosanol on lipid profile in primary hypercholesterolemia.

Francini-Pesenti F, Beltramolli D, Dall'acqua S, Brocadello F.

Phytother Res. 2008 Mar;22(3):318-22. doi: 10.1002/ptr.2315.

PMID:
18167048
8.

Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts.

Menendez R, Fernandez SI, Del Rio A, Gonzalez RM, Fraga V, Amor AM, Mas RM.

Biol Res. 1994;27(3-4):199-203.

PMID:
8728831
9.

Cholesterol-lowering effects of policosanol in rabbits.

Arruzazabala ML, Carbajal D, Mas R, Molina V, Valdes S, Laguna A.

Biol Res. 1994;27(3-4):205-8.

PMID:
8728832
10.

Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women.

Mirkin A, Mas R, Martinto M, Boccanera R, Robertis A, Poudes R, Fuster A, Lastreto E, Yañez M, Irico G, McCook B, Farré A.

Int J Clin Pharmacol Res. 2001;21(1):31-41.

PMID:
11708573
11.

Effects of policosanol on postmenopausal women with type II hypercholesterolemia.

Castaño G, Más R, Fernández L, Fernández JC, Illnait J, López LE, Alvarez E.

Gynecol Endocrinol. 2000 Jun;14(3):187-95.

PMID:
10923280
12.

Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.

Crespo N, Illnait J, Más R, Fernández L, Fernández J, Castaño G.

Int J Clin Pharmacol Res. 1999;19(4):117-27.

PMID:
10939029
13.

Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations.

Lin Y, Rudrum M, van der Wielen RP, Trautwein EA, McNeill G, Sierksma A, Meijer GW.

Metabolism. 2004 Oct;53(10):1309-14.

PMID:
15375787
14.

Concomitant use of policosanol and beta-blockers in older patients.

Castaño G, Mas R, Gámez R, Fernández J, Illnait J, Fernández L, Mendoza S, Mesa M, Gutiérrez JA, López E.

Int J Clin Pharmacol Res. 2004;24(2-3):65-77.

PMID:
15689053
15.

Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits.

Gámez R, Máz R, Arruzazabala ML, Mendoza S, Castaño G.

Drugs R D. 2005;6(1):11-9.

PMID:
15806713
16.

A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.

Castaño G, Más R, Fernández L, Illnait J, Mendoza S, Gámez R, Fernández J, Mesa M.

Drugs Exp Clin Res. 2005;31 Suppl:31-44.

PMID:
16444910
17.
18.

Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.

Más R, Castaño G, Illnait J, Fernández L, Fernández J, Alemán C, Pontigas V, Lescay M.

Clin Pharmacol Ther. 1999 Apr;65(4):439-47.

PMID:
10223782
19.

Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.

Castaño G, Menéndez R, Más R, Amor A, Fernández JL, González RL, Lezcay M, Alvarez E.

Int J Clin Pharmacol Res. 2002;22(3-4):89-99.

PMID:
12837046
20.

Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk.

Castaño G, Más R, Fernández JC, Illnait J, Fernández L, Alvarez E.

J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M186-92.

PMID:
11253161

Supplemental Content

Support Center